O2 RegenTech
About this raise
O2 RegenTech, with a valuation of $6.8 million, is raising funds on NetCapital. The company is using its proprietary biopolymer technology to commercialize easy-to-use wound care solutions. O2 RegenTech’s first product is called OXAID and is a moist, oxygenating, and antimicrobial dressing that promotes chronic wound healing. It is a one-of-a-kind wound solution that is cost-effective and easy to use and helps chronic wounds heal faster and at a lower cost than other oxygen delivery systems. Dr. Andreas Inmann and Dr. Nic Leipzig founded O2 RegenTech in July 2013. The current crowdfunding campaign has a minimum target of $10,002.80 and a maximum target of $612,000. The campaign proceeds will be used for product development, regulatory affairs, operations, payroll, and biocompatibility testing.
Investment Overview
Not Funded: $2,033
Deal Terms
Company & Team
Company
- Year Founded
- 2013
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Financials
-
Revenue
-
$0
as of FY2023
- Monthly Burn
-
$2,338
as of FY2023
-
Runway
-
0.8 months
as of FY2023
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $0
- VC Backed?
- No
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
04/30/2025 | Netcapital | $6,800,000 | $2,033 | Equity - Common | Not Funded | RegCF |